Tampa, Florida 33612


The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.


Inclusion Criteria: - Men 18 years of age or older - Diagnosis of adenocarcinoma of the prostate, confirmed by H.L. Moffitt Cancer Center review - No prior treatment for prostate cancer - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1 - Prostate Cancer Clinical Stage T2a and below - PSA <10 ng/ml (this will be the prostatic specific antigen (PSA) level prompting the initial prostate biopsy) - Prostate size <60 cc on transrectal ultrasound - Pre-enrollment biopsy parameters (as per H.L. Moffitt C.C. review): Minimum of 10 biopsy cores; Gleason score 6 aor 7; Unilateral cancer (only right-sided or left-sided, not bilateral). Exclusion Criteria: - Men less than 18 years of age - Medically unfit for anesthesia - Histology other than adenocarcinoma - Biopsy does not meet inclusion criteria - Men who have received any hormonal manipulation (antiandrogens; Luteinizing Hormone Releasing Hormone (LHRH) agonist; 5-alpha-reductase inhibitors) within the previous 6 months



Primary Contact:

Principal Investigator
Julio Pow-Sang, M.D.
H. Lee Moffitt Cancer Center and Research Institute

Backup Contact:


Location Contact:

Tampa, Florida 33612
United States

Jesse Mocha, B.S.
Phone: 813-745-2629
Email: jesse.mocha@moffitt.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.